Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Eribulin
Drug ID BADD_D00798
Description Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors [A7439].
Indications and Usage For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.
Marketing Status Prescription
ATC Code L01XX41
DrugBank ID DB08871
KEGG ID D08914
MeSH ID C490954
PubChem ID 11354606
TTD Drug ID D0XQ5X
NDC Product Code Not Available
Synonyms eribulin | E 7389 | E-7389 | ER-086526 | ER086526 | ER 086526 | ER-86526 | Halaven | NSC 707389 | NSC707389 | NSC-707389 | B 1793 | B-1793 | B 1939 | B-1939 | eribulin mesylate | eribulin monomethanesulfonate | eribulin mesilate | eribulin (as mesylate)
Chemical Information
Molecular Formula C40H59NO11
CAS Registry Number 253128-41-5
SMILES CC1CC2CCC3C(=C)CC(O3)CCC45CC6C(O4)C7C(O6)C(O5)C8C(O7)CCC(O8)CC(=O)CC9C(CC(C1=C)O 2)OC(C9OC)CC(CN)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Epistaxis24.07.01.005; 22.04.03.001--
Erythema23.03.06.001--Not Available
Erythema infectiosum23.03.08.007; 11.05.15.0020.000533%Not Available
Erythropenia01.07.02.0010.000533%Not Available
Extravasation08.01.03.0080.001332%Not Available
Eye disorder06.08.03.001--Not Available
Face oedema23.04.01.004; 08.01.07.003; 10.01.05.0020.000533%
Fatigue08.01.01.002--
Febrile neutropenia08.05.02.004; 01.02.03.0020.042093%
Gait disturbance17.02.05.016; 08.01.02.002--
Gastric ulcer07.04.03.0020.000533%
Gastric ulcer haemorrhage24.07.02.003; 07.04.03.0050.000533%Not Available
Gastrooesophageal reflux disease07.02.02.003--
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Generalised oedema14.05.06.007; 08.01.07.0040.001066%
Haematemesis24.07.02.011; 07.12.02.0020.000139%Not Available
Haematocrit decreased13.01.05.0010.000533%Not Available
Haematuria24.07.01.047; 20.02.01.006--
Haemoglobin decreased13.01.05.003--Not Available
Headache17.14.01.001--
Hepatic cirrhosis09.01.04.0010.000278%Not Available
Hepatic failure09.01.03.0020.000486%
Hepatic function abnormal09.01.02.0010.002398%Not Available
Hepatic steatosis14.08.04.005; 09.01.07.0030.000533%Not Available
Hepatocellular injury09.01.07.0080.000533%Not Available
Hepatotoxicity12.03.01.008; 09.01.07.0090.001332%Not Available
Herpes zoster23.09.03.002; 11.05.02.003--
Hyperbilirubinaemia09.01.01.003; 14.11.01.010; 01.06.04.0030.000799%Not Available
Hypercalcaemia14.04.01.003; 05.04.01.0020.000799%
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 9 Pages